Clinical trial · Interventional
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
NCT00038597CI-TRIAL-00035512completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myelogenous Leukemia, Chronic | Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SCH66336 | Drug | Lonafarnib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
* Diagnosis of Philadelphia chromosome (Ph) -positive CML in chronic or accelerated phase; * Failure to respond to or intolerance to imatinib mesylate (Gleevec); * Age \>/= 16 years; * Life expectancy of \>/= 2 months; * Performance status 2 or better (Zubrod); * Adequate renal and hepatic functions (creatinine and bilirubin \</= 2 mg/dl); * Adequate cardiac function; * Not candidates for or have refused allogeneic transplantation; * Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole), macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs (phenobarbital, phenytoin, carbamazepine), rifampin or isoniazid.
References
Publications (0)
Data not yet available
No reference posted for this study.